Statements (71)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:accessories |
global pandemic
|
| gptkbp:advocacy |
required for trials
|
| gptkbp:analysis |
ongoing
|
| gptkbp:business_model |
adhered to
|
| gptkbp:clinical_trial |
gptkb:Bayer_AG
thousands Phase 1 multiple countries Phase 2 Phase 3 pending publication reduction in symptoms |
| gptkbp:clinical_trial_duration |
several months
|
| gptkbp:clinical_trial_results_publication |
anticipated in 2024
|
| gptkbp:collaborates_with |
other pharmaceutical companies
|
| gptkbp:collaborations |
academic institutions
international organizations |
| gptkbp:collection |
real-world evidence
|
| gptkbp:community_engagement |
healthcare initiatives
|
| gptkbp:community_health |
ongoing
|
| gptkbp:community_outreach |
health education programs
|
| gptkbp:competitors |
other antiviral treatments
|
| gptkbp:developed_by |
gptkb:Bayer_AG
|
| gptkbp:dosage_form |
twice daily
|
| gptkbp:eligibility |
specific health conditions
|
| gptkbp:feedback |
collected during trials
|
| gptkbp:financial_support |
available
|
| gptkbp:funding |
public and private sources
government grants private investments |
| gptkbp:healthcare |
improved through partnerships
|
| https://www.w3.org/2000/01/rdf-schema#label |
Bayer's COVID-19 treatment
|
| gptkbp:impact |
potential to change treatment landscape
|
| gptkbp:intended_use |
treatment of mild to moderate COVID-19
|
| gptkbp:invention |
patented
|
| gptkbp:is_effective_against |
reduces hospitalization rates
|
| gptkbp:is_monitored_by |
adverse effects
during treatment |
| gptkbp:market_position |
expected in 2024
|
| gptkbp:mechanism_of_action |
inhibits viral replication
|
| gptkbp:outcome |
improved recovery times
|
| gptkbp:part_of |
Bayer's COVID-19 response strategy
|
| gptkbp:partnerships |
government health agencies
|
| gptkbp:patient_education |
available
|
| gptkbp:patient_population |
adults
high-risk individuals |
| gptkbp:provides_information_on |
with global health organizations
|
| gptkbp:publication_year |
gptkb:2023
|
| gptkbp:publications |
peer-reviewed journals
|
| gptkbp:recruitment |
ongoing
|
| gptkbp:regulatory_approval_status |
under review
|
| gptkbp:regulatory_body |
gptkb:FDA
gptkb:EMA |
| gptkbp:research_focus |
COVID-19 variants
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:safety_features |
monitored during trials
|
| gptkbp:safety_measures |
independent board
|
| gptkbp:scientific_goals |
improve treatment outcomes
|
| gptkbp:side_effect |
fatigue
headache nausea |
| gptkbp:supply_chain |
global distribution network
critical for distribution |
| gptkbp:targets |
gptkb:COVID-19
|
| gptkbp:training |
ongoing
|
| gptkbp:treatment |
monitored post-treatment
|
| gptkbp:type |
gptkb:immunotherapy
|
| gptkbp:type_of_care |
monitored during trials
|
| gptkbp:bfsParent |
gptkb:Lonza_Group
|
| gptkbp:bfsLayer |
6
|